MAMuhammad Imtiaz Ahmad

Muhammad Imtiaz Ahmad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammad Imtiaz Ahmad has a total of 120 co-authors. Here are the top co-authors by number of shared publications:

  • Elsayed Z. Soliman

    Epidemiological Cardiology Research Center, Department of Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC

    18 shared publications
  • Elsayed Z. Soliman

    Epidemiological Cardiology Research Center (EPICARE), Department of Internal Medicine, Cardiovascular Section Wake Forest School of Medicine Winston‐Salem North Carolina USA

    14 shared publications
  • Muhammad Ali Anees

    Department of Internal Medicine, Texas Tech University, Amarillo, Texas, United States

    8 shared publications
  • Yabing Li

    Epidemiological Cardiology Research Center (EPICARE), Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, United States of America

    8 shared publications
  • Parag Anilkumar Chevli

    Wake Forest University School of Medicine

    7 shared publications
  • Elsayed Z Soliman

    Department of Epidemiology and Prevention, Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine , Winston-Salem, North Carolina , USA

    5 shared publications

Latest Publications

  • Open Access

    Effect of IL-6 inhibition on lipoprotein(a) levels: A systematic review and meta-analysis

    by Saeid Mirzai, James McParland, Muhammad Imtiaz Ahmad, Emil Degoma, John Walsh, Michael D. Shapiro


  • Open Access

    Lipoprotein(a), Insulin Resistance, and Cardiovascular Disease in the UK Biobank

    by Richard Kazibwe, Christopher L. Schaich, Parag A. Chevli, Jeff A. Kingsley, Saeid Mirzai, Juliana H. Namutebi, Muhammad Imtiaz Ahmad, Anurag Mehta, Harpreet S. Bhatia, Mitchell Paukner, et al.

    Background: Insulin resistance (IR) and lipoprotein(a), Lp(a), are established contributors to cardiovascular disease (CVD) risk. Whether IR modifies the association between Lp(a) and CVD in primary prevention remains uncertain. Methods: This prospective cohort study included UK Biobank participants without baseline CVD. IR at enrollment was assessed using the triglyceride‐glucose index (TyG). The primary outcome was first major adverse cardiovascular event, defined as peripheral arterial disease, coronary artery disease, myocardial infarction, ischemic stroke, or cardiovascular death. Cox models estimated adjusted hazard ratios (aHRs) with 95% CIs for log‐transformed Lp(a) and TyG, adjusting for each other. Lp(a) was categorized as P ‐value for the multiplicative interaction between TyG and Lp(a) was 0.07. Relative to reference, aHRs (95% CI) were 1.15 (1.10–1.20) for ≥125/low IR, 1.09 (1.06–1.12) for <125/high IR, and 1.32 (1.24–1.41) for ≥125/high IR. Conclusions: Lp(a) and IR each independently contribute to cardiovascular risk, with a combination offering improved risk stratification. This suggests that accounting for IR may enhance the assessment of Lp(a)‐associated risk in the context of primary CVD prevention setting.


  • Open Access

    Association between cardiovascular-kidney-metabolic syndrome, inflammatory biomarkers, and cardiovascular outcomes: Insights from the MESA study

    by Muhammad Imtiaz Ahmad, Parag Chevli, Saeid Mirzai, Jared A. Spitz, Garima Sharma, Joao Lima, Khurram Nasir, Michael J. Blaha, Neha J. Pagidipati, Roger S. Blumenthal, et al.


  • Open Access

    Effect of Intensive Blood Pressure Lowering on the Risk of Incident Silent Myocardial Infarction: A Post Hoc Analysis of a Randomized Controlled Trial

    by Richard Kazibwe, Muhammad Imtiaz Ahmad, Sanjay Singh, Lin Y. Chen, Elsayed Z. Soliman

    Background: Silent myocardial infarction (SMI) frequently goes undetected, yet it is associated with increased cardiovascular morbidity and mortality. The impact of intensive systolic blood pressure (SBP) lowering on the risk of SMI in those with hypertension remains uncertain.Methods: In this post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT), participants with serial electrocardiograms (ECGs) during the trial were included. SPRINT investigated the benefit of intensive SBP lowering, aiming for < 120 mmHg compared to the standard SBP goal of < 140 mmHg. Incident SMI was defined as evidence of new MI on an ECG without adjudicated recognized myocardial infarction (RMI).Results: During a median follow‐up of 3.9 years, a total of 234 MI events (55 SMI and 179 RMI) occurred. Intensive, compared to standard, SBP lowering resulted in a lower rate of SMI (incidence rate 1.1 vs. 2.3 cases per 1000 person‐years, respectively; HR [95% CI]: 0.48 [0.27–0.84]). Similarly, intensive, compared to standard, BP lowering reduced the risk of RMI (incidence rate 4.6 vs. 6.5 cases per 1000 person‐years, respectively; HR [95% CI]: 0.71 [0.52–0.95]). No significant differences were noted between the strength of the association of intensive BP control on lowering the risk of SMI and RMI (p‐value for HR differences = 0.23).Conclusions: This study shows that in adults with hypertension, the benefits of intensive SBP lowering, compared with standard BP lowering, go beyond the prevention of RMI to include the prevention of SMI.Trial Registration: ClinicalTrials.gov Identifier: NCT01206062.

  • Open Access

    Exploring the Link between Anticoagulation, Cognitive Impairment and Dementia in Atrial Fibrillation: A Systematic Review

    by Abhimanyu Agarwal, Mohamed A. Mostafa, Muhammad Imtiaz Ahmad, Elsayed Z. Soliman

    Background: The impact of oral anticoagulants (OACs) on cognitive impairment and dementia in patients with atrial fibrillation (AF) is not well characterized. This systematic review aims to address this knowledge gap. Methods: SCOPUS and PubMed searches were conducted to identify articles in the English language investigating the association between the use of OACs and cognitive impairment and dementia. We excluded non-original research studies and studies that did not report data on cognitive impairment or included patients who underwent open heart surgery or had psychiatric illnesses or cancer. Results: Out of 22 studies (n = 606,404 patients), 13 studies (n = 597,744 patients) reported a reduction in cognitive impairment/dementia in those undergoing thromboprophylaxis. Using direct oral anticoagulants (DOACs) was associated with a lower incidence of cognitive impairment in 10 studies (n = 284,636 patients). One study found that patients undergoing dual therapy (n = 6794 patients) had a greater incidence of cognitive impairment compared to those undergoing monotherapy (n = 9994 patients). Three studies (n = 61,991 patients) showed that AF patients on DOACs had a lower likelihood of dementia diagnosis than those on vitamin K antagonists (VKAs). Dementia incidence was lower when VKAs were under good control. Conclusions: The use of oral anticoagulants has the potential to prevent cognitive impairment and dementia in patients with AF. Since most of the published research on this subject is observational in nature, more randomized controlled trials are needed to fully understand the effect of anticoagulants on cognitive function.


  • Open Access

    Association between Blood Lead Levels and Silent Myocardial Infarction in the General Population

    by Mohamed A. Mostafa, Mohammed A. Abueissa, Mai Z. Soliman, Muhammad Imtiaz Ahmad, Elsayed Z. Soliman

    Background: Although the link between lead exposure and patterns of cardiovascular disease (CVD) has been reported, its association with silent myocardial infarction (SMI) remains unexplored. We aimed to assess the association between blood lead levels (BLLs) and SMI risk. Methods: We included 7283 (mean age 56.1 ± 2.52 years, 52.5% women) participants free of CVD from the Third National Health and Nutrition Examination Survey. BLL was measured using graphite-furnace atomic absorption spectrophotometry. SMI was defined as ECG evidence of myocardial infarction (MI) without history of MI. The association between SMI and BLLs was examined using multivariable logistic regression. Results: SMI was detected in 120 participants with an unweighted prevalence of 1.65%. Higher BLL correlated with higher SMI prevalence across BLL tertiles. In multivariable-adjusted models, participants in the third BLL tertile had more than double the odds of SMI (OR: 3.42, 95%CI: 1.76–6.63) compared to the first tertile. Each 1 µg/dL increase in BLL was linked to a 9% increase in SMI risk. This association was consistent across age, sex, and race subgroups. Conclusions: Higher BLLs are associated with higher odds of SMI in the general population. These results underscore the significance of the ongoing efforts to mitigate lead exposure and implement screening strategies for SMI in high-risk populations.


  • Open Access

    Association between Blood Lead Levels and Silent Myocardial Infarction in the General Population.

    by Mohamed A. Mostafa, Mohammed A. Abueissa, Mai Z. Soliman, Muhammad Imtiaz Ahmad, Elsayed Z. Soliman

    Background: Although the link between environmental lead exposure and several patterns of cardiovascular disease (CVD) has been reported, its association with silent myocardial infarc-tion (SMI) has not been explored. We aimed to assess the association between blood lead levels (BLL) and risk of SMI. Methods: This analysis included 7283 (mean age 56.1±2.52 years, 52.5% women) participants from the Third National Health and Nutrition Examination Survey who were free of clinical CVD. Ascertainment of BLL done using graphite furnace atomic absorption spectrophotometry. SMI defined as ECG evidence of MI without history of MI. Multivariable lo-gistic regression analysis was used to examine the association between SMI and BLL. Results: SMI was detected in 120 participants corresponding to an unweighted prevalence of 1.65%. Par-ticipants with higher levels of BLL had higher prevalence of SMI (0.4%, 0.9%, and 2.4% across BLL tertiles; p-value

  • Open Access

    Joint Association of Albuminuria and Left Ventricular Hypertrophy with Incident Heart Failure in High-Risk Adults with Hypertension: a SPRINT substudy

    by Muhammad Imtiaz Ahmad, Richard Kazibwe, Mai Z. Soliman, Sanjay Singh, Lin Y. Chen, Elsayed Z. Soliman

    Background: Albuminuria and left ventricular hypertrophy (LVH) are independent predictors of heart failure (HF), however their combined effect on risk of HF has not been explored previously. Objectives: To examine the joint associations of albuminuria and electrocardiographic (ECG) LVH with incident acute decompensated HF (ADHF), and whether albuminuria/LVH combinations modified the effects of blood pressure control strategy in reducing the risk of ADHF. Methods: 8,511 participants from the SPRINT (Systolic Blood Pressure Intervention Trial) were included. ECG-LVH was present if any of the following criteria: Cornell voltage, Cornell voltage product, or Sokolow Lyon were present. Albuminuria was defined as urine albumin-creatinine ratio (UACR) ≥30 mg/g. ADHF was defined as hospitalization or emergency visit for ADHF. Cox proportional hazard models were used to examine the association of neither LVH, nor albuminuria (reference), either LVH or albuminuria, and both (LVH + albuminuria) with incident ADHF. Results: Over a median follow-up of 3.2 years, 182 cases of ADHF occurred. In adjusted models, concomitant albuminuria and LVH were associated with higher risk of ADHF than either albuminuria or LVH in isolation (HR (95% CI): 4.95 (3.22-7.62), 2.04 (1.39-3.00), and 1.47 (0.93-2.32), respectively (additive interaction p =0.01). The effect of intensive blood pressure in decreasing ADHF attenuated among participants with co-existing albuminuria and LVH without any interaction between treatment group assignment and albuminuria/LVH categories (interaction p-value= 0.26). Conclusions: Albuminuria and LVH are additive predictors of ADHF. The effect of intensive blood pressure control in decreasing ADHF risk did not vary significantly across albuminuria/LVH combinations. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01206062


  • Open Access

    Association of Empirical Dietary Inflammatory Potential with Mortality: Results from the Third National Nutrition Examination Survey

    by Mohamed A. Mostafa, Travis Skipina, Muhammad Ali Anees, Elsayed Z. Soliman, Muhammad Imtiaz Ahmad

    Background: The empirical dietary inflammatory potential (EDIP) score is designed to assess the inflammatory potential of a diet based on the pro- and anti-inflammatory properties of its various components. This study examined the association of EDIP with all-cause mortality in a large, community-based, multiracial sample of the United States population. Study Design: A prospective cohort study. Methods: This analysis included 13155 participants (44.6±18.4 years, 54.21% women, and 40.33% White) without prior history of cardiovascular disease (CVD) from the Third National Health and Nutrition Examination (NHANES III) Survey. A 24-hour dietary recall information was used to calculate EDIP. The National Death Index was employed to identify the date and cause of death. Cox proportional hazard analysis was utilized to evaluate the association between the tertiles of EDIP and all-cause mortality over a median follow-up of 26.6 years. Results: In a model adjusted for demographics and CVD risk factors, a higher EDIP tertile, compared with the lowest tertile, was associated with an increased risk of all-cause mortality (hazard ratio [HR]=1.10; 95% CI: 1.02, 1.19). A standard-deviation increase in EDIP (0.27 units) was related to a 4% increased risk of mortality (HR=1.04; 95% CI: 1.01, 1.08). This association was stronger in older participants compared to younger ones (HR=1.09; 95% CI: 0.98, 1.21 vs. HR=0.89; 95% CI: 0.80, 1.01), respectively, interaction P=0.030)]. Conclusion: Pro-inflammatory diet is associated with an increased risk of mortality, especially in the older population. Dietary changes that reduce inflammation may have the potential to reduce the risk of poor outcomes.